Stay updated with breaking news from Ian Churcher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the...
Summit for pioneers in PROTACs, molecular glues, bifunctionals beyond PROTACs and the Induced proximity modality space
Summit for pioneers in PROTACs, molecular glues, bifunctionals beyond PROTACs and the Induced proximity modality space
Ian Churcher of Amphista highlights opportunities and how the next generation of targeted protein degradation (TPD) therapy are developing to overcome existing limitations.